KUHNIL PRODUCT PROFILE

YOUR COMMITTED GLOBAL PARTNER

KUHNIL PHARM

ABOUT KUHNIL

A global pharmaceutical company leading the way in improving the quality of life

With the belief that our state-of-the-art facilities and top-tier researchers are secured through bold investments, and that the life and health of citizens are protected, we are poised to make a powerful start in the development of the world's leading new drugs.

Established	1969
Headquarter/ R&D Center	Seoul, Korea
Manufacturing site	Cheonan, Korea
Sales	93 million USD
No. of employees	325
Homepage	www.kuhnil.com

KUHNIL GROUP



PENMIX CO. LTD.
CMO Specialized Company
(Penicillin / Injection Formulation)

KUHNIL PHARM. CO. LTD.
Prescription Drug-Oriented
Pharmaceutical Company
(Fully-integrated pharma company)

OHSONG PHARM CO. LTD.
Import / Export of Pharmaceutical products
and APIs for the Japanese market.

KUHNIL BIOPHARM CO. LTD.
Generics CSO business Company
for the Korean market

BRIO PHARMA CO., LTD.
CMO Specialized Company
(Penicillin / Injection Formulation)

HISTORY OF KUHNIL

1960

1969 Kuhnil Yakpum established
1977 Technical partnership with Merck Corp.
1986 Technical partnership with Wyeth-Ayerst International Inc. for Lodine®(Etodolac)

1990

1990 KGMP Plant approved
1991 License agreement with Schering-Plough Corp.
1992 R&D Center approved
License agreement with Lek (Sandoz) Corp. for Amocla®(Amoxicilin-Clavulanic acid)
1997 Changed the company name from Kuhnil Yakpum to Kuhnil Pharm
Expansion of the Kuhnil Central R&D Center
1998 Technical & License agreement with Biocodex Corp. for Bioflor®

2000

2002 Penmix established (affiliate of Kuhnil)
2004 Technical & License agreement with Pronova Corp. for Omacor® (Omega-3)
2005 License agreement with YM BioSciences Corp., Biosyntech Corp. and Cubist Corp.
2007 License agreement with TTY Biotech Corp.
2008 License agreement with Emcure Corp.
2009 STH Pharm and Ohsong Pharm established (affiliates of Kuhnil)

2010

2010 Relocation of the Head quarter to Jeong-dong, Seoul
2011 R&D Center consolidation/relocation into Seoul head quarter
2012 Technical & License agreement with Neurim for Circadin® (Melatonin SR)
2016 Technical & License agreement with Neurim for Slenyto® (Melatonin SR)
2017 License agreement with Kitov
Brio Pharma established (affiliates of Kuhnil)
Rosumega® (Rosuvastatin plus omega-3) launched
2018 Export & License agreement with S.P.A Corp. for Rosumega®
2019 Approval of EU-GMP for second plant

2020

2020 Registered Rosumega® in Europe and Mongolia
Kuhnil Bio Pharm established (affiliates of Kuhnil)
2022 Atomega® (Atovastatin plus omega-3) launched
Export & License agreement with Siegfried Rhein S.A. de C.V for Rosumega®
2023 License agreement with A.forall
License agreement with Mochida for Epadel® (EPA)

GLOBAL PARTNERSHIP

Global Partnership

Year	Company	Nation	Product	Category
1977	Merck	U.S.A	Clidol	NSAID
1982	Zambeletti	Italy	Difenax	NSAID
1986	Inverni	Italy	Mucoril	Muscle Relaxant
1986	MerrellDow	U.S.A	Teldane	Anti-histamine
1986	AHP (Wyeth)	U.S.A	Lodine®	NSAID
1991	Schering-Plough	U.S.A	Netromycin	Antibiotic
1991	Schering-Plough	U.S.A	Celestamine	Anti-histamine
1992	Lek(Sandoz)	Slovenia	Amocla®	Antibiotic
1994	Solco	Switzerland	Solcosplen	Postmenopausal
1998	Biocodex	France	Bioflor®	Probiotic
2004	Pronova	Norway	Omacor®	Anti-hyperlipidemia
2005	YM BioSciences	Canada	Nimotuzumab	Anti-cancer
2005	Regulon	Greece	Liposomal cisplatin	Anti-cancer
2005	Cubist	U.S.A	Cubicin	Antibiotic
2005	Biosyntech	Canada	BST-CarGel®	Orthopedic
2007	TTY Biotech	Taiwan	Liposomal doxorubicin	Anti-cancer
2008	Emcure	India	R-Sibutramine	Anti-obesity
2012	Neurim	Israel	Circadin®	Sleep disorder
2016	Neurim	Israel	Slenyto®	Pediatric Sleep Disorder
2017	Kitov	Israel	Celecoxib+Amlodipine	Arthritis
2024	A.forall	Belgium	Fluticasone furoate	Allergic rhinitis
2024	Mochida	Japan	Epadel®	Hyperlipidemia

Current Status of Global Partners

Nation	Company	Logo
Israel	Neurim Pharmaceuticals	
Israel	Kitov Pharmaceuticals	
France	Biocodex	
Germany	BASF	
Korea	Daiichi-Sankyo	
Korea	Ferring	
Netherlands	Synthon	
Belgium	A.forall	
Japan	Mochida	
Mexico	Siegfried Rhein	

R&D CENTER

Vision and Goal

- Establish specialized platform technologies and patent proprietary technologies.
- Develop R&D products based on technical convergence to gain a global-level technological competitive edge.
- Develop new combination drugs, modify formulations, side effect improvements, and discover new indications based on platform technologies.
- Upgrade technologies to target not only the domestic market but also the global market.
- Focus on core disease areas: cardiovascular diseases, oncology, and autoimmune diseases.
- Enter advanced pharmaceutical markets by developing first generics, especially high-potency drugs.



R&D Pipeline

Field	Indication	Project Name	Target Market	Stage of Development
Oncology	Leukemia	KI3149	EU, etc.	Research
Oncology	Breast cancer	KI3142	Japan & EU, etc.	Research
Oncology	Renal cell carcinoma	KI3149	Japan & EU, etc.	Research
Oncology	Renal cell carcinoma	KI3137	Japan	Research
Oncology	Hyperlipidemia	KI1127	Korea	Research
Cardiovascular	Hyperlipidemia	KI1137	Korea	Research
Cardiovascular	Hyperlipidemia	KI1135	Korea	Research
Cardiovascular	Hyperlipidemia	KI1122	Korea	PV production
Cardiovascular	Hyperlipidemia	KI1136	Mexico	PV production
Cardiovascular	Pulmonary hypertension	KI3151	Japan	PV production
Cardiovascular	Hyperlipidemia	KI1114	Korea	Launched
Cardiovascular	Hyperlipidemia	KI1107	Korea / EU	Launched

KUHNIL PRODUCTION

Manufacturing site

Located in Cheonan, Korea

Land Area : 45,940 ㎡

Building Area: 6,365 ㎡

Facility

- Oral Solids Production Line (tablet, granule, soft capsule)
- Highly Potent Oral Solids pilot production Line
- Animal laboratory (isolated building)
- Automation warehouse (1,950 Cell)

Production Available Formulation

- Oral solids (tablet, granule, soft capsule)
- Highly Potent oral solids

GMP Status

- KGMP approved (since 1990)
- EU GMP approved (since 2019)

GLOBAL GMP SYSTEM

We, Kuhnil Pharm, strictly comply the guidelines of global GMP and constantly strive for quality system improvement.



Chemical test

Data Integrity utilization

Microbial test

Endotoxin test, Microbial limit test

Animal test

Histamine test, Innocuity test, Hemolysis test

Main Product

KUHNILPHARM PRODUCT LIST

Name	Product	Ingredient Content	Indications and Usage	Packing Unit / Shelf life
Omacor Soft Cap.		Omega-3 acid ethyl ester 90 ... 1000㎎ (EPA ethyl ester 460mg, DHA ethyl ester 380mg)	Treatment of endogenous hypertriglyceridemia: 1. Type IV hypertriglyceridemia in monotherapy. 2. TypeIIb combined hyperlipidemia (mixed type of hypercholesterolemia and hypertriglyceridemia) in combination with statins. 3. TypeIIb combined hyperlipidemia (mixed type of hypercholesterolemia and hypertriglyceridemia) in combination with statins, when control of triglycerides is shown to be insufficient.	100 Capsule /case 30 Capsule /case 36 months
Rosumega Soft Cap.		Omega-3 acid ethyl ester 90 ... 1000㎎ Rosuvastatin Calcium ... 5.20㎎ (5㎎ as rosuvstatin)	Treatment of mixed dyslipidemia (Type IIb) characterized by controlled LDL-C levels with statin monotherapy but persistent elevation of triglycerides	100 Capsule /case 30 Capsule /case 36 months
Atomega Soft Cap.		Omega-3-acid ethylesters 90... 1,000㎎ Atorvastatin Calcium... 5.425㎎ (5㎎ as Atorvastatin)	Treatment of mixed dyslipidemia (Type IIb) characterized by controlled LDL-C levels with statin monotherapy but persistent elevation of triglycerides	80 Capsule /case 18 months
Amocla Duo Tab. (Amoxicillin:Clavulanate 7:1)		(500mg) Amoxicillin Hydrate ... 437.55㎎ Potassium Clavulanate diluted ... 107.765㎎	Treatment of acute/chronic bronchitis, lobar and bronchial pneumonia, empyema, lung abscess, tonsillitis, sinusitis, otitis media, cystitis, urethritis, pyelonephritis, pelvic infections, gonorrhea, furuncles and abscesses, cellulitis, wound infections, osteomyelitis, or dental abscesses.	100 Tablet/case
		(1000mg) Amoxicillin Hydrate ... 8755㎎ Potassium Clavulanate diluted ... 215.525㎎		24 months
Amocla Duo Syrup (dry) (Amoxicillin:Clavulanate 7:1)		(500ml) Amoxicillin Hydrate ... 36.326g/100g (405㎎/ml) Potassium Clavulanate diluted ... 10.352g/100g	Treatment of acute/chronic bronchitis, lobar and bronchial pneumonia, empyema, lung abscess, tonsillitis, sinusitis, otitis media, cystitis, urethritis, pyelonephritis, pelvic infections, gonorrhea, furuncles and abscesses, cellulitis, wound infections, osteomyelitis, or dental abscesses.	500ml/bottle 24 months

Cardiovascular system

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Omacor Soft Cap.		Omega-3-acid ethylesters 90... 1,000㎎ (EPA ethylester... 460㎎, DHA ethylesters... 380㎎, α-tocopherol... 4㎎)	This drug is indicated as an adjunct to diet to reduce elevated triglyceride levels in patients with the following types of endogenous hypertriglyceridemia: 1. Type Ⅳ hypertriglyceridemia in monotherapy. 2. Type Ⅱb mixed hyperlipidemia (mixed type of hypercholesterolemia and hypertriglyceridemia) in combination with statins. 3. Type Ⅱb mixed hyperlipidemia (mixed type of hypercholesterolemia and hypertriglyceridemia) in combination with statins, when control of triglycerides is shown to be insufficient.	Patients should be placed on an appropriate lipid-lowering diet before receiving this drug and should continue this diet during treatment with this drug. This drug should be taken with food to avoid gastrointestinal disturbances. Usual dose for hypertriglyceridemia: The starting dose is 2 g/day (2 capsules daily). If adequate response is not obtained, the daily dose may be increased up to 4 g (4 capsules daily). Once or twice daily
Omacormini Soft Cap.		Omega-3-acid ethylesters90... 2,000㎎ (EPA ethylester... 920㎎, DHA ethylester... 760㎎, α-tocopherol... 8㎎)	Indications and Usage: This drug is indicated as an adjunct to diet to reduce elevated triglyceride levels in patients with the following types of endogenous hypertriglyceridemia: 1. Type Ⅳ hypertriglyceridemia in monotherapy. 2. Type Ⅱb mixed hyperlipidemia (mixed type of hypercholesterolemia and hypertriglyceridemia) in combination with statins. 3. Type Ⅱb mixed hyperlipidemia (mixed type of hypercholesterolemia and hypertriglyceridemia) in combination with statins, when control of triglycerides is shown to be insufficient.	Dosage and Administration: Patients should be placed on an appropriate lipid-lowering diet before receiving this drug and should continue this diet during treatment with this drug. This drug should be taken with food to avoid gastrointestinal disturbances. Usual dose for hypertriglyceridemia: The starting dose is 2 g/day (2 capsules daily). If adequate response is not obtained, the daily dose may be increased to 4 g (4 capsules daily). Once or twice daily.
Rosumega Soft Cap.		Omega-3-acid ethylesters 90... 1000.00㎎, Rosuvastatin calcium... 5.20㎎ (5㎎ as Rosuvastatin)	Indications and Usage: This drug is indicated for treatment of mixed hyperlipidemia (Type Ⅱb) in adults with high risk of coronary heart disease (CHD), when control of triglycerides is shown to be insufficient in rosuvastatin monotherapy, while low-density lipoprotein cholesterol (LDL-C) is adequately controlled.	Dosage and Administration: Patients should be placed on an appropriate lipid-lowering diet before receiving this drug and should continue this diet during treatment with this drug. This drug should be used for adults only, with food to avoid gastrointestinal disturbances. 2 to 4 capsules once daily (each capsule: Omega-3-acid ethyl esters/Rosuvastatin, 1000 mg/5 mg). (For further information, see the package insert.)
Atomega Soft Cap.		Omega-3-acid ethylesters 90... 1,000㎎, Atorvastatin Calcium... 5.425㎎ (5㎎ as Atorvastatin)	Indications and Usage: This drug is indicated for treatment of mixed hyperlipidemia (Type Ⅱb) in adults with high risk of coronary heart disease (CHD), when control of triglycerides is shown to be insufficient in atorvastatin 20 mg monotherapy, while low-density lipoprotein cholesterol (LDL-C) is adequately controlled.	Dosage and Administration: Patients should be placed on an appropriate lipid-lowering diet before receiving this drug and should continue this diet during treatment with this drug. This drug should be used for adults only, with food to avoid gastrointestinal disturbances. 4 capsules once daily (each capsule: Omega-3-acid ethyl esters/Atorvastatin, 1000 mg/5 mg).
Mevalotin Tab. **5mg, 10mg, 20mg, 40mg**		Pravastatin sodium... 5㎎, 10㎎, 20㎎, 40㎎	Indications and Usage: This drug is indicated: 1. Primary hyperlipidemia: hypercholesterolemia (type IIa), mixed hyperlipidemia (type IIb) (mixed type of hypercholesterolemia and hypertriglyceridemia). 2. Reduction of the risk of myocardial infarction onset and coronary death in the following high-risk groups of patients with hypercholesterolemia or mixed hyperlipidemia. 3. Reduction of the risk of myocardial infarction, myocardial revascularization procedures, ischemic stroke, and transient ischemic attack in patients with a history of myocardial infarction or unstable angina pectoris.	Patients should be placed on an appropriate low lipid diet before receiving this drug and should continue this diet during treatment with this drug. The usual starting dose is 10 mg, 20 mg, or 40 mg as a single dose once daily. If adequate response is not obtained, the daily dose may be increased up to 40 mg. The maintenance dose is 10-40 mg once daily.
Repitapa Tab. **1mg, 2mg**		Pitavastatin calcium... 1㎎, 2㎎	This drug is indicated as: 1. An adjunct to diet in patients with primary hypercholesterolemia and mixed dyslipidemia. 2. An adjunct to diet in patients aged 10 to 16 years with heterozygous familial hypercholesterolemia (HeFH).	1. Patients with primary hypercholesterolemia and mixed dyslipidemia: The dose of pitavastatin calcium is 1-2 mg once daily. The daily dose may be increased up to 4 mg. 2. Patients aged 10 to 16 years with HeFH: The dose of pitavastatin calcium is 1 mg once daily. The daily dose may be increased up to 2 mg.

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Apito Tab. 10mg, 20mg		Atorvastatin calcium trihydrate... 10.85㎎ (10㎎ as Atorvastatin)... 21.7㎎ (20㎎ as Atorvastatin)	This drug is indicated: 1. Reduction of the risk of cardiovascular disease. 2. Hyperlipidemia. 3. Pediatrics aged 10 to 17 years with heterozygous familial hypercholesterolemia (HeFH), when the response to diet is inadequate.	1. Hyperlipidemia: The recommended dose range is 10-80 mg once daily. 2. Pediatrics with HeFH (aged 10 to 17 years). (For further information, see the package insert.)
Amilo Tab.		Amiloride HCl... 5㎎	This drug is indicated in patients with congestive heart failure, hypertension with normal renal function, or hepatic cirrhosis with ascites.	5-10 mg/day. (For further information, see the package insert.)
Kuhnil Clopidogrel Tab.		Clopidogrel hydrogen sulfate... 97.875㎎ (75 ㎎as Clopidogrel)	This drug is indicated for: 1. Symptomatic treatment of atherosclerosis in patients with ischemic stroke, myocardial infarction or peripheral arterial disease. 2. Symptomatic treatment of atherosclerosis in patients with acute coronary syndrome. 3. Reduction of the risk of atherothrombosis and thromboembolism including stroke in adults with atrial fibrillation and those who have a low bleeding risk and at least one risk factor for vascular events, which are not suitable for treatment with vitamin K antagonists (VKA).	1. Patients with ischemic stroke, myocardial infarction, or peripheral arterial disease: 75 mg once daily. 2. Patients with acute coronary syndrome: The starting dose is 300 mg once daily. The maintenance dose is 75 mg once daily (in combination with 75-325 mg of aspirin once daily). 3. Patients with atrial fibrillation: 1 tablet once daily (in combination with 75-100 mg of aspirin once daily). (For further information, see the package insert.)

Endocrine Systema

KUHNILPHARM PRODUCT LIST

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Kuhnil Glimepiride Tab.		Glimepiride... 2㎎	This drug is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.	Once daily orally (with at least 1/2 cup of water), before breakfast or the first main meal of the day. It is very important not to skip a meal after taking this medication.

Digestive system

KUHNILPHARM PRODUCT LIST

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Bioflor 250 Powder		Saccharomyces boulardii... 282.5㎎ (With at least 5 × 10^9 CFU of live bacteria)	This drug is indicated for treatment of various symptoms caused by dysbiosis (due to administration of antibiotics, chemotherapy drugs, etc.): diarrhea, constipation, loose stool, abdominal bloating, or intestinal abnormal fermentation.	Over 12 years of age (1-2 packets/capsules, twice daily). 3 to 12 years of age (1 packet/capsule, 3 times daily). Under 3 years of age (1 packet/capsule, twice daily).
Bioflor 250 Cap.				
Wellcon Tab.		Calcium Polycarbophil... 625.0㎎	This drug is indicated for diarrhea treatment and an adjuvant therapy of constipation in patients with chronic constipation, nonspecific diarrhea, or irritable bowel syndrome.	Adults (2 tablets 1 to 4 times daily). Pediatrics (aged 6 to 12 years: 1 tablet 1 to 3 times daily).

Antibiotics

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Amocla Tab. **187.5mg, 375mg, 625mg**		**(187.5mg)** Amoxicillin... 125㎎, Pot, Clavulanate... 62.5㎎ **(375mg)** Amoxicillin... 250㎎, Pot, Clavulanate... 125mg **(625mg)** Amoxicillin... 500㎎, Pot, Clavulanate... 125㎎	This drug is indicated in patients with acute/chronic bronchitis, lobar and bronchial pneumonia, empyema, lung abscess, tonsillitis, sinusitis, otitis media, cystitis, urethritis, pyelonephritis, pelvic infections, gonorrhea, furuncles and abscesses, cellulitis, wound infections, osteomyelitis, or dental abscesses.	1. Adults and pediatrics (aged 12 years or older, or over 40 kg): Amoxicillin/clavulanate potassium 250/125 mg as a single dose, 3 times daily orally with 8-hour intervals. For severe infections or respiratory infections, the daily dose may be increased to amoxicillin/clavulanate potassium 500/125 mg as a single dose. 2. For renal impairment, the daily dose may be increased or decreased appropriately depending on the creatinine clearance. 3. For dental abscesses, amoxicillin 250 mg as a single dose, 3 times daily for 5 days.
Amocla Duo Tab. **500mg, 1000mg**		Amoxicillin... 437.5㎎, Pot, Clavulanate... 62.5㎎	This drug is indicated in patients with acute/chronic bronchitis, lobar and bronchial pneumonia, empyema, lung abscess, tonsillitis, sinusitis, otitis media, cystitis, urethritis, pyelonephritis, pelvic infections, gonorrhea, furuncles and abscesses, cellulitis, wound infections, osteomyelitis, or dental abscesses.	1 tablet twice daily orally with 12-hour intervals.
Amocla Syrup(4:1)		Amoxicillin... 1,250㎎, Clavulanate... 3.125㎎	This drug is indicated in patients with acute/chronic bronchitis, lobar and bronchial pneumonia, empyema, lung abscess, tonsillitis, sinusitis, otitis media, cystitis, urethritis, pyelonephritis, pelvic infections, gonorrhea, furuncles and abscesses, cellulitis, wound infections, osteomyelitis, or dental abscesses.	For mild to moderate infections, amoxicillin/clavulanate potassium 20 mg/5 mg/kg daily (0.8 mL/kg/day). For severe infections, amoxicillin/clavulanate potassium 40 mg/10 mg/kg daily (1.6 mL/kg/day), in both cases taken in three divided doses.
Amocla Duo Syrup(7:1)		Amoxicillin... 2,000㎎, Pot. Clavulanate... 285㎎	This drug is indicated in patients with acute/chronic bronchitis, lobar and bronchial pneumonia, empyema, lung abscess, tonsillitis, sinusitis, otitis media, cystitis, urethritis, pyelonephritis, pelvic infections, gonorrhea, furuncles and abscesses, cellulitis, wound infections, osteomyelitis, or dental abscesses.	For mild to moderate infections, amoxicillin/clavulanate potassium 25 mg/3.6 mg/kg daily (0.625 mL/kg/day). For severe infections, amoxicillin/clavulanate potassium 45 mg/6.4 mg/kg daily (1.125 mL/kg/day), in both cases taken in two divided doses.
Amocla Inj. **0.6g, 1.2g**		**(0.6g)** Amoxicillin sodium ... 500㎎, Pot. Clavulanate ... 100㎎ **(1.2g)** Amoxicillin sodium... 1000㎎, Pot. Clavulanate... 200㎎	This drug is indicated in patients with acute/chronic bronchitis, lobar and bronchial pneumonia, empyema, lung abscess, tonsillitis, sinusitis, otitis media, cystitis, urethritis, pyelonephritis, pelvic infections, gonorrhea, furuncles and abscesses, cellulitis, wound infections, peritonitis, osteomyelitis, or postoperative infections.	See the package insert.
Vantin Dry Syrup **50mg/5mL**		Cefpodoxime Proxetil... 5,000㎎	This drug is indicated in patients with: - Furuncles, furunculosis, carbuncles, contagious impetigo, cellulitis, lymphangitis, subcutaneous abscesses. - Pharyngitis (retropharyngeal abscesses), acute bronchitis, tonsillitis (peritonsillitis, peritonsillar abscess), pneumonia. - Pyelonephritis, cystitis. - Otitis media, sinusitis. - Scarlet fever.	Pediatrics: Cefpodoxime 3 mg/kg (3 mg (potency)/kg of body weight) as a single dose, 2 to 3 times daily orally, prepared in suspension. For severe cases or cases where adequate response is not obtained, 4.5 mg/kg (4.5 mg (potency)/kg of body weight)) as a single dose, 3 times daily orally.
Cefrozil Tab. **250mg**		Cefprozil... 250㎎	This drug is indicated in patients with upper respiratory tract infections (pharyngitis, tonsillitis, otitis media, acute sinusitis), lower respiratory tract infections (secondary bacterial infection of acute bronchitis and acute bacterial exacerbation of chronic bronchitis), skin and soft tissue infections, or uncomplicated genito-urinary tract infections (including cystitis).	See the package insert.
Cefrozil Dry Syrup **125mg/5mL**		Cefprozil... 5,000㎎/100g	This drug is indicated in patients with lower respiratory tract infections (e.g. bronchitis, pneumonia), upper respiratory tract infections (e.g. pharyngitis, tonsillitis, sinusitis), acute otitis media, skin and skin tissue infections, or mycobacterial infections.	7.5 mg/kg of pediatrics' body weight daily with 12-hour intervals (15 mg/kg/day). The usual administration period is 5 to 10 days.

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Klaris Tab. **250mg**		Clarithromycin... 250㎎	This drug is indicated: Lower respiratory tract infections (e.g. bronchitis, pneumonia), upper respiratory tract infections (e.g. pharyngitis, sinusitis), skin and skin tissue infections, or mycobacterial infections. Helicobacter pylori eradication in peptic (duodenal and gastric) ulcer disease.	Adults: 1 tablet twice daily. For severe infections, 2 tablets twice daily. The usual administration period is 7 to 14 days.
Tabaxin Inj. **2.25g, 4.5g**		**(2.25g)** Piperacillin sodium... 2g, Tazobactam... 0.25g **(4.5g)** Piperacillin sodium... 4g, Tazobactam... 0.5g	This drug is indicated in: 1. Adults: Pneumonia, genito-urinary tract infections other than prostatitis, intra-abdominal infections and cholecystitis, skin infections, fever and infections in patients with neutropenia, bacterial sepsis. 2. Pediatrics: Fever and infections in patients with neutropenia, appendicitis with complications (e.g. peritonitis, abscess).	This drug is indicated in: 1. Adults and pediatrics aged 12 years or older: The usual dose is 4.5 g 3 times daily with 8-hour intervals. The daily dose may be increased up to 18 g. 2. Pediatrics aged 12 years or younger: Neutropenia. - For pediatrics weighing 50 kg or less, 90 mg/kg with 6-hour intervals in combination with aminoglycosides. Appendicitis with complications. - For pediatrics aged 2 to 12 years and weighing 40 kg or less, 112.5 mg/kg with 8-hour intervals.
Tazobaxin Inj. **2.25g, 4.5g**		**(2.25g)** Piperacillin sodium...2g, Tazobactam ... 0.25g **(4.5g)** Piperacillin sodium... 4g, Tazobactam... 0.5g	This drug is indicated in: 1. Adults: Pneumonia, geni to-urinary tract infections other than prostatitis, intra-abdominal infections and cholecystitis, skin infections, fever and infections in patients with neutropenia, bacterial sepsis. 2. Pediatrics: Fever and infections in patients with neutropenia, appendicitis with complications (e.g. peritonitis, abscess).	This drug is indicated in: 1. Adults and pediatrics aged 12 years or older: The usual dose is 4.5 g 3 times daily with 8-hour intervals. The daily dose may be increased up to 18 g. 2. Pediatrics aged 12 years or younger: Neutropenia. - 90 mg/kg with 6-hour intervals in combination with aminoglycosides. Appendicitis with complications. - For pediatrics aged 2 to 12 years and weighing 40 kg or less, 112.5 mg/kg with 8-hour intervals.
Ampibactam Inj.		Ampicillin sodium··· 500㎎, Sulbactam sodium··· 250㎎	This drug is indicated: Upper/lower respiratory tract infections (including otitis media, epiglottitis, and sinusitis), bacterial pneumonia, urinary tract infections, pyelonephritis, intra-abdominal infections (including peritonitis, cholecystitis, endometritis, and pelvic cellulitis), skin and soft tissue infections, bone and joint infections, or gonorrhea. Prevention of postoperative infections after procedures (intra-abdominal and gynecological infections).	1. Adults: 0.5-3 g (potency) 3 to 4 times daily by intravenous or intramuscular injection. The maximum daily dose is sulbactam 4g (potency). 2. Newborns, infants, children: 60-150 mg (potency)/kg daily, divided into 3 to 4 times. Newborns, especially preterm infants, are administered in two divided doses (with 12-hour intervals) for the first week after birth.
Daptocin Inj. **350mg**		Daptomycin··· 350㎎	This drug is indicated in adults with: 1. Complicated skin and skin/soft tissue infections caused by Gram-positive bacteria. 2. Staphylococcus aureus bacteremia including right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.	Complicated skin and skin/soft tissue infections: 4 mg /kg/24 hours. Endocarditis/bacteremia: 6 mg/kg/24 hours.

Nervous · Psychiatric system

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Circadin PR Tab. **2mg(melatonin)**		Melatonin... 2mg	This drug is indicated for short-term treatment of insomnia characterized by poor quality of sleep in patients aged 55 years or older.	1 tablet once daily orally 1-2 hours before bedtime and after food. The tablet should be swallowed whole without chewing or crushing. This dosage may be continued for up to 13 weeks.
Slenyto PR Tab. **1mg, 5mg**		Melatonin Micronized ... 1mg, 5mg	This drug is indicated for treatment of insomnia in pediatrics aged 2 to 18 years with autism spectrum disorder and/or Smith-Magenis syndrome, when symptoms are not relieved despite good sleep hygiene.	1. The recommended starting dose is 2 mg once daily. If adequate response is not obtained, the daily dose may be increased to 5 mg. The maximum daily dose is 10 mg. 2. Once daily orally 0.5 to 1 hour before bedtime with or after food. The tablet should be swallowed whole without chewing or crushing.
Kuhnil Gabapentin Cap. **300mg**		Gabapentin... 300mg	This drug is indicated in patients with epilepsy or neuropathic pain.	1. 1st day: 300 mg of this drug once daily or 100 mg of this drug 3 times daily. 2. 2nd day: 300 mg of this drug twice daily or two 100 mg capsules 3 times daily. 3. 3rd day: 300 mg of this drug 3 times daily or three 100 mg capsules 3 times daily.
Kuhnil Tianeptine Tab.		Sodium tianeptin... 12.5mg	This drug is indicated for treatment of major depressive disorders.	Adults: 1 tablet 3 times daily before meals. (This dose should be reduced to 2 times daily for elderly patients over 70 years of age or patients with renal failure.)

Musculoskeletal system

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Kuhnil Lodine Tab. **200mg**		Etodolac micronized... 200mg	This drug is indicated in patients with rheumatoid arthritis, osteoarthritis (degenerative, arthritis), ankylosing spondylitis, or post-surgical/post-traumatic/post-tooth extraction pain.	Pediatrics aged 3 months or older: The recommended dose of this drug is 90 mg/kg/day based on amoxicillin 600 mg/5 mL with 12-hour intervals for 10 days (acute otitis media) or 7 days (acute sinusitis).
Lodine XL Tab. **400mg**		Etodolac micronized... 400mg	This drug is indicated in patients with rheumatoid arthritis or osteoarthritis.	Adults: Once daily (400-800 mg).
Kuhnil Lodine SR Tab. **600mg**		Etodolac micronized... 600mg	This drug is indicated in patients with rheumatoid arthritis, osteoarthritis (degenerative, arthritis), or ankylosing spondylitis.	600 mg (1 tablet) once daily.
Celbrox Cap. **200mg**		Celecoxib... 200mg	This drug is indicated for 1. Treatment of symptoms or signs of osteoarthritis (degenerative arthritis). 2. Treatment of symptoms or signs of rheumatoid arthritis. 3. Treatment of symptoms or signs of ankylosing spondylitis. 4. Treatment of acute pain (post-surgical, post-tooth extraction pain) in adults. 5. Treatment of primary dysmenorrhea.	1. Osteoarthritis (degenerative arthritis): Celecoxib 200 mg once daily or 100 mg twice daily. 2. Rheumatoid arthritis: Celecoxib 100 mg once or 200 mg twice daily.

Respiratory system

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Pulmican Suspension for Nebulize		Budesonide micronized... 0.5㎎/2ml	This drug is indicated for treatment of bronchial asthma (when other treatments, especially steroid therapy, are insufficient or inadequate) and acute laryngotracheobronchitis (croup) in pediatrics.	1. Early stages of bronchial asthma: For adults, 2-4 bottles once daily. For pediatrics, 1-2 bottles twice daily. Maintenance: For adults, 1-2 bottles once daily. For pediatrics, 0.5-1 bottle twice daily. 2. Acute laryngotracheobronchitis: For pediatrics, 2 mg once daily.
Brophil Cap. **100mg**		Acebrophylline... 100㎎	This drug is indicated in patients with acute/chronic respiratory diseases associated with respiratory obstruction disorder and mucus secretion disorder: Acute/chronic bronchitis, bronchial asthma, sinusitis, rhinitis sicca.	1 capsule twice daily.
Kuhnil Montelukast Fine Granule. **4mg**		Montelukast... 4㎎, 5㎎, 10㎎	This drug is indicated for: 1. Prevention and continuous treatment of asthma. 2. Symptomatic treatment of seasonal and year-round allergic rhinitis.	Once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized depending on patient condition. For patients with both asthma and seasonal allergic rhinitis, 1 tablet and 1 packet daily in the evening.
Kuhnil Montelukast Tab. **10mg**				
Kuhnil Montelukast Chewable Tab. **5mg**				
Kuhnil Montelukast Chewable Tab. **4mg**				
Kuhnil Levodropropizine Tab.		Levodropropizine... 60㎎	This drug is indicated in patients with cough associated with acute and chronic bronchitis.	Adults: Levodropropizine 60 mg 3 times daily orally with at least 6-hour intervals.
Kuhnil Levodropropizine Syrup		Levodropropizine... 600㎎/100ml	This drug is indicated in patients with cough associated with acute and chronic bronchitis.	1. Adults: Levodropropizine 60 mg 3 times daily orally with at least 6-hour intervals. 2. Pediatrics: Levodropropizine with at least 6-hour intervals. - Weighing 10 to 20 kg: 18 mg 3 times daily orally. - Weighing 20 to 30 kg: 30 mg 3 times daily orally.

Others

Name	Product	Ingredient Content	Indications and Usage	Dosage and Administration
Zomacton Inj. **10mg**		Somatropin... 10㎎	: This drug is indicated for: 1. Treatment of growth disturbance associated with insufficient secretion of pituitary growth hormone in pediatrics. 2. Treatment of growth disturbance associated with Turner syndrome.	1. Patients with pituitary growth hormone deficiency: 0.5-0.70 IU/kg/week (0.17-0.23 mg/kg/week) by subcutaneous injection. 2. Patients with Turner syndrome: 1.0 IU/kg/week (0.3 mg/kg/week) by subcutaneous injection.
Prandin Tab. **6mg**		Deflazacort micronized... 6㎎	This drug is indicated in patients with rheumatic disorders and connective tissue diseases, skin diseases, allergic diseases, respiratory diseases, ophthalmic diseases, hematopoietic diseases, gastrointestinal diseases, liver diseases, or kidney diseases.	Deprazacort 6-90 mg daily orally (for pediatrics, the daily dose should be increased or decreased appropriately depending on the disease, age, and symptoms).

KUHNIL PHARM
Head office : Ohsong B/D, 14, Jeongdong-gil, Jung-gu, Seoul, Republic of Korea
www.kuhnil.com